Baby Vaccine Study (Sched3)
Information source: University of Oxford
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Infectious Diseases
Intervention: DTaP/IPV/Hib vaccine (Biological); 13 valent Pneumococcal Conjugate Vaccine (Biological); Rotavirus vaccine (Biological); 4-component Meningococcal B vaccine (Biological); Meningococcal C/Hib vaccine (MenC/Hib vaccine) (Biological); Measles/Mumps/Rubella Vaccine (MMR vaccine) (Biological)
Phase: Phase 2
Status: Not yet recruiting
Sponsored by: University of Oxford Official(s) and/or principal investigator(s): Matthew D Snape, Principal Investigator, Affiliation: Oxford Vaccine Group, Chief Investigator
Overall contact: Matthew D Snape, Phone: 01865857420, Email: matthew.snape@paediatrics.ox.ac.uk
Summary
This multicentre, parallel group, block randomised clinical trial aims to investigate the
post booster antibody response in UK infants given a reduced priming schedule of
meningococcal serogroup B vaccine and 13 valent pneumococcal conjugate vaccine. It will
provide information about how best to include the meningococcal B vaccine (likely to be
introduced late 2015) into the routine immunisation schedule.
The UK Department of Health provides a routine vaccination schedule for children in the UK
and are advised by the Joint Committee on Vaccination and Immunisation (JCVI). The
Department of Health have announced that the meningococcal B vaccine (Bexsero) be introduced
to the routine schedule as a 2+1 schedule. Cost effectiveness could also be improved by
removing the current MenC conjugate vaccine dose given at 3 months of age. There is no
published immunogenicity data for Bexsero when given at 2, 4 and 12 months of age (2+1
schedule) and with concomitant Infanrix/IPV/Hib which has now replaced Pediacel in the
infant programme.
This change to the schedule would result in three injections at 2, 4 and 12 months, and
given previous reluctance among parents for three injections at one visit, an option to
reduce PCV13 to a 1+1 schedule (priming dose at 3 months and booster at 12 months) will be
assessed in this study.
Clinical Details
Official title: Assessment of Post Booster Antibody Responses in UK Infants Given a Reduced Priming Schedule of Meningococcal Serogroup B and 13 Valent Pneumococcal Conjugate Vaccines
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Primary outcome: Pneumococcal serotype specific geometric mean concentrations (GMCs) in blood samples following the completion of either a 2, 4 and 12 month schedule of PCV13 vaccination, or only 3 and 12 month PCV13 vaccination
Secondary outcome: 13 serotype-specific pneumococcal IgG GMCs and functional pneumococcal antibodies and proportions greater than or equal to ≥0.35µg/mL for each serotype in blood samples taken at 5 and 13 monthsTitres and proportions of participants achieving antibody responses to MenB vaccination human Serum Bactericidal Antibody (SBA) titres ≥4 for the three main vaccine antigen target MenB strains, 5/99 (NadA), NZ98/254 (PorA) and 44/76-SL (fHbp) Meningococcal serogroup C human SBA geometric mean titres (GMTs) and proportion of infants ≥4 (5 month blood only); rabbit SBA titres (GMT) and proportion of infants with titres 8 and 128 (13 month blood only) Meningococcal serogroup W hSBA GMTs and proportion of infants with titre ≥4 at 5 and 13 months of age GMC of anti-PRP IgG [Hib antigen] and proportion of infants with concentrations of > 0.15µg/mL and 1.0µg/mL in the blood samples taken at 5 and 13 months of age GMC of IgG to pertussis antigens (PT, PRN, FHA and FIM 2 and 3) in the blood samples taken at 5 months of age GMC of anti-tetanus toxoid IgG and proportions ≥0.1 IU/mL and ≥1.0 IU/mL in the blood samples taken at 5 months of age GMC of anti-diphtheria toxoid IgG and proportions ≥0.1IU/mL and ≥1.0 IU/mL in the blood samples taken at 5 months of age Frequency of carriage of identified pneumococcal serotypes from the nasal swab collected prior to the booster vaccinations at 12 months of age and six months later Number of participants with local adverse events at injection site and temperature as recorded in the daily health diary for the week following vaccination and any systemic symptoms. Temperature also recorded and analysed from the iButton system
Detailed description:
The study's primary objective is to assess antibody response to the pneumococcal vaccine
after the final infant vaccinations at approximately 13 months of age, and secondary
objectives include antibody response following meningococcal B and C vaccines, tetanus,
diphtheria and pertussis vaccines. In addition, the effect of maternal pertussis vaccination
in pregnancy on infant immune response to vaccines, the prevalence of carriage of
pneumococcal serotypes at 12 and 18 months of age and reactogenecity following each vaccine
will be assessed.
200 healthy children who have not yet received their routine infant immunisations will be
enrolled between 8 and 12 weeks old. Participants will be randomised into one of two groups
with differing vaccine schedules. Children in both groups will receive their routine
immunisations with the following changes: the addition of 3 doses of a meningococcal B
vaccine at 2, 4 and 12 months and a meningococcal C vaccine at 12 months only (instead of a
dose at 3 and 12 months). The 2 groups will differ by the number of doses of the 13-valent
pneumococcal vaccine (PCV13); to be given either at 2, 4, and 12 months of age (as currently
given in the routine schedule) or at 3 and 12 months of age.
Each participant will have 2 blood tests: at 5 and 13 months of age, and 2 nose swabs: at 12
and 18 months of age to address the objectives of the study. Parents will be asked to
complete a health diary to record any adverse events in the 7 days following vaccinations
and a continuous thermometer (ibutton) will be used to record the temperature for 24 hours
after each vaccination.
If the blood samples at 13 months reveal antibody titres that are below the level indicative
of protection, a recommendation will be made for booster vaccinations.
Eligibility
Minimum age: 8 Weeks.
Maximum age: 12 Weeks.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Infants due to receive their primary immunisations , aged up to 13 weeks on first
vaccinations.
- Written informed consent given by mother who is aged >= 16 years [NB mother is
preferable as consent also allows permission to record the date of pertussis
immunisation in pregnancy, which may need to be verified in her medical record. Where
mother is not available, consent may be taken from father or legal guardian and
maternal pertussis status noted as not known]
Exclusion Criteria:
- Bleeding disorder
- Fulfil any of the contraindications to vaccination as specified in The Green Book
[https://www. gov. uk/government/organisations/public-health-england/series/immunisation-against-infectious-disease-the-green-book]:
- At risk of invasive pneumococcal disease (IPD) as defined in the Green Book
pneumococcal chapter and those born prior to 37 weeks gestation
- Confirmed anaphylactic reaction to a previous dose of the vaccine, or
- Confirmed anaphylactic reaction to any constituent or excipient of the vaccine(s).
- A confirmed anaphylactic reaction to neomycin, streptomycin or polymyxin B (which may
be present in trace amounts in the tetanus vaccine) and/or kanamycin, histidine,
sodium chloride or sucrose (which may be present in trace amounts in the MenB
vaccine).
- Latex hypersensitivity (the syringe cap of Bexsero may contain natural rubber latex)
Locations and Contacts
Matthew D Snape, Phone: 01865857420, Email: matthew.snape@paediatrics.ox.ac.uk Additional Information
Starting date: August 2015
Last updated: June 23, 2015
|